Organophosphate and Carbamate Poisoning Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Organophosphate and Carbamate Poisoning Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Organophosphate and Carbamate Poisoning - Drugs In Development, 2022, provides an overview of the Organophosphate and Carbamate Poisoning (Toxicology) pipeline landscape.
Organophosphates and carbamates are common insecticides that inhibit cholinesterase activity, causing acute muscarinic manifestations (salivation, lacrimation, urination, diarrhea, emesis, bronchorrhea, bronchospasm, bradycardia, miosis) and some nicotinic symptoms, including muscle fasciculations and weakness. Most patients have bradycardia and, if poisoning is severe, hypotension. CNS toxicity is common, sometimes with seizures and excitability and often with lethargy and coma. Pancreatitis is possible, and organophosphates may cause arrhythmias such as heart block and QTc interval prolongation.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Organophosphate and Carbamate Poisoning - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Organophosphate and Carbamate Poisoning (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Organophosphate and Carbamate Poisoning (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Organophosphate and Carbamate Poisoning and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical stages are 5 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.
Organophosphate and Carbamate Poisoning (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Organophosphate and Carbamate Poisoning (Toxicology).
  • The pipeline guide reviews pipeline therapeutics for Organophosphate and Carbamate Poisoning (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Organophosphate and Carbamate Poisoning (Toxicology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Organophosphate and Carbamate Poisoning (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Organophosphate and Carbamate Poisoning (Toxicology)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Organophosphate and Carbamate Poisoning (Toxicology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Organophosphate and Carbamate Poisoning (Toxicology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Organophosphate and Carbamate Poisoning – Overview
Organophosphate and Carbamate Poisoning – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Organophosphate and Carbamate Poisoning – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Organophosphate and Carbamate Poisoning – Companies Involved in Therapeutics Development
AntoXa Corp
Countervail Corp
PlantVax Inc
Shanghai Leado Pharmaceutical Technology Co Ltd
Organophosphate and Carbamate Poisoning – Drug Profiles
AM-132 – Drug Profile
galantamine hydrobromide – Drug Profile
LD-04001 – Drug Profile
PlantVax-1502-HN – Drug Profile
Recombinant Butyrylcholinesterase for Carbamate and Organophosphate Poisoning – Drug Profile
RS-194B – Drug Profile
Small Molecule for Organophosphate Poisoning – Drug Profile
Small Molecules to Activate Acetylcholinesterase for Organophosphate Poisoning – Drug Profile
Small Molecules to Agonize GABAA for Nerve Gas and Organophosphate Poisoning – Drug Profile
Organophosphate and Carbamate Poisoning – Dormant Projects
Organophosphate and Carbamate Poisoning – Discontinued Products
Organophosphate and Carbamate Poisoning – Product Development Milestones
Featured News & Press Releases
Feb 21, 2016: Israeli parent patent for the use of Galantamine and Antimuscarinic Agent For Organophosphorus Poisoning awarded
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Table 1: Number of Products under Development for Organophosphate and Carbamate Poisoning, 2022
Table 2: Number of Products under Development by Companies, 2022
Table 3: Number of Products under Development by Universities/Institutes, 2022
Table 4: Products under Development by Companies, 2022
Table 5: Products under Development by Universities/Institutes, 2022
Table 6: Number of Products by Stage and Target, 2022
Table 7: Number of Products by Stage and Mechanism of Action, 2022
Table 8: Number of Products by Stage and Route of Administration, 2022
Table 9: Number of Products by Stage and Molecule Type, 2022
Table 10: Organophosphate and Carbamate Poisoning – Pipeline by AntoXa Corp, 2022
Table 11: Organophosphate and Carbamate Poisoning – Pipeline by Countervail Corp, 2022
Table 12: Organophosphate and Carbamate Poisoning – Pipeline by PlantVax Inc, 2022
Table 13: Organophosphate and Carbamate Poisoning – Pipeline by Shanghai Leado Pharmaceutical Technology Co Ltd, 2022
Table 14: Organophosphate and Carbamate Poisoning – Dormant Projects, 2022
Table 15: Organophosphate and Carbamate Poisoning – Discontinued Products, 2022
List of Figures
Figure 1: Number of Products under Development for Organophosphate and Carbamate Poisoning, 2022
Figure 2: Number of Products under Development by Universities/Institutes, 2022
Figure 3: Number of Products by Targets, 2022
Figure 4: Number of Products by Stage and Targets, 2022
Figure 5: Number of Products by Mechanism of Actions, 2022
Figure 6: Number of Products by Stage and Mechanism of Actions, 2022
Figure 7: Number of Products by Routes of Administration, 2022
Figure 8: Number of Products by Stage and Routes of Administration, 2022
Figure 9: Number of Products by Molecule Types, 2022
Figure 10: Number of Products by Stage and Molecule Types, 2022

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings